FDA approves Exforge and Diovan HCT

The US FDA has approved Diovan HCT (valsartan/hydrochlorothiazide) and Exforge (amlodipine/ valsartan), as first-line therapies in patients who need multiple drugs to achieve their blood pressure goals.

Angiotensin II receptor antagonists slow rate of progressive aortic-root dilation in Marfans

Data published in this weeks NEJM show that angiotensin II receptor antagonists delay the progression of aortic root dissection in patients with Marfan’s syndrome

Shionogi and Dainippon Sumitomo to launch Irbesartan in Japan on July 1st

Shionogi and Dainippon Sumitomo have announced that Irbesartan will be launched in Japan on July 1st. Shionogi licensed Irebesartan, a long-acting angiotensin II receptor blocker, from Sanofi-Aventis.

Daiichi-Sankyos Angiotensin II 1 antagonist olmesartan reverses blood vessel damage

Olmesartan medoxomil has been found to be effective at reversing the narrowing of the arteries that occurs in patients with hypertension. Treatment improved structural abnormalities of resistance arteries.

Ore outline progress with AT1-R research

Ore Pharmaceuticals have outlined research that shows Candesartan and Angiotensin II type 1 receptor antagonists to be effective in breast cancer

Azor shows efficacy in difficult to treat patient groups

Data presented at ASH shows that Azor (amlodipine and olmesartan medoxomil) safely and effectively lowered blood pressure, especially in several key difficult to treat patient groups such as in those of African and Hispanic/Latino decent

Phase I results with Pharmacopeias PS-433540

Phase I results with Pharmacopeia’s Dual acting Endothelin A/Angiotensin II 1 antagonist presented at the American Society of Hypertension meeting

Benicar effective at restoring normotension

45% of hypertension patients treated with Daiichi Sankyo’s Angiotensin II 1 antagonist Benicar (olmesartan) reach normotension

Exforge treatment effective in black patients

Black patients treated with Exforge (Amlodipine/Valsartan) have been show to experience a significantly higher reduction in systolic blood pressure than those on amlodipine alone

Forest and Daiichi Sankyo end Azor co promotion agreement

Forest has terminated it’s co-promotion agreement for Azor (amlodipine and olmesartan medoxomil) with Daiichi Sankyo. Forest has determined that its resources will be better utilized in providing additional support for Forest’s currently marketed products.